MALLIK AMEET 4

What Happened

• Ameet Mallik, CEO of ADC Therapeutics (ADCT), received an award of 675,000 restricted stock units (RSUs) on June 30, 2026. The Form 4 reports the acquisition as an award (code A) with an acquisition price of $0.00 (i.e., no cash paid at grant). The filing lists the grant amount but does not provide a cash market value for the grant on the filing itself.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-02 (timely filing within the SEC two-business-day window).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 675,000 RSUs; acquisition price reported: $0.00; total reported cost: $0.
• Shares owned after transaction: not specified in the information provided on this filing.
• Footnote: RSUs vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the company without cause or by the reporting person for good reason, subject to continued employment on the vesting date. Each RSU represents a contingent right to receive one share of common stock.

Context

• RSUs are a form of equity compensation that convert into shares upon vesting; this award is compensation rather than an open-market purchase or sale. The filing does not indicate any immediate sale, tax-withholding shares, or a 10b5-1 plan. As a grant, it signals management compensation alignment with shareholders but should not be interpreted alone as a buy/sell market signal.